BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/23/2022 2:39:01 PM | Browse: 433 | Download: 1122
 |
Received |
|
2022-01-29 10:29 |
|
Peer-Review Started |
|
2022-01-29 10:31 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-04-10 20:57 |
|
Revised |
|
2022-04-16 16:18 |
|
Second Decision |
|
2022-05-09 03:15 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-14 08:04 |
|
Articles in Press |
|
2022-05-14 08:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-05-26 08:00 |
|
Publish the Manuscript Online |
|
2022-06-23 14:39 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Fibrosis regression following hepatitis C antiviral therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Aisha Mahmoud Elsharkawy, Reham Samir and Mohamed El-Kassas |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mohamed El-Kassas, MD, MSc, PhD, Professor, Department of Endemic Medicine, Faculty of Medicine, Helwan University, Helwan, Cairo 11795, Egypt. m_elkassas@hq.helwan.edu.eg |
| Key Words |
Fibrosis regression; Hepatitis C virus; Direct-acting antivirals; Hepatocellular carcinoma; Liver fibrosis; Cirrhosis |
| Core Tip |
Hepatitis C virus (HCV) infection is one of the most common causes of hepatitis that results in continuous liver injury. Uncontrolled inflammatory responses result in liver fibrosis and cirrhosis. Liver fibrosis is a dynamic process that can be reversible upon timely cessation of the injurious agent. In cases of HCV, achievement of sustained virological response by antiviral therapies might be accompanied by regression of liver fibrosis and improvement of the patient's clinical profile. Assessment of liver fibrosis can be done with invasive and non-invasive methods, with certain limitations. Fibrosis regression can positively impact patients' quality of life, reducing complications. |
| Publish Date |
2022-06-23 14:39 |
| Citation |
Elsharkawy A, Samir R, El-Kassas M. Fibrosis regression following hepatitis C antiviral therapy. World J Hepatol 2022; 14(6): 1120-1130 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i6/1120.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i6.1120 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
